COVID-19 Testing and Prevention in Correctional Settings (045)

Study Information

COVID-19 case rates among incarcerated individuals are five times higher compared to the general public.

Yale University received a supplement to support a study to increase the reach, access, uptake, and impact of COVID-19 testing and to mitigate the impact of COVID-19 among incarcerated people and corrections staff. The initiativeโ€™s multidisciplinary team will be working with jails and prisons across Florida, Rhode Island, Minnesota, and Washington to address the urgent need for the development and implementation of long-term COVID-19 testing and prevention strategies. The long-term goal is to mitigate the impact of COVID-19 in correctional facilities while considering the ethical issues that must be addressed to optimize implementation and effectiveness.

This project was provided as a supplement to the National Institute on Drug Abuse (NIDA) from the NIH Rapid Acceleration of Diagnostics Underserved Populations (RADx-UP) program.


Study Settings: Jails/Prisons

Study Locations:ย Florida, Minnesota, Rhode Island, Washington

Study Team

PI: Lauren Brinkley-Rubinstein, Rosemarie Martin, PhD, Emily Wang

Logo of Yale School of Medicine

Study Aims

โ€ข Identify ethical concerns and potential solutions for COVID-19 testing and vaccine strategies in correctional facilities using a community-engaged strategy

โ€ข Characterize incidence of COVID-19, disease progression, and related-outcomes and effectiveness of testing and contact tracing (among staff and people who are incarcerated) in correctional facilities

โ€ข Mitigate the impact of COVID-19 in correctional facilities while considering the ethical issues that must be addressed to optimize implementation and effectiveness

Research Type

COVID-19 Testing, RADX-UP Supplement